Stephan Bart

937 total citations · 1 hit paper
19 papers, 438 citations indexed

About

Stephan Bart is a scholar working on Infectious Diseases, Epidemiology and Immunology. According to data from OpenAlex, Stephan Bart has authored 19 papers receiving a total of 438 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Infectious Diseases, 12 papers in Epidemiology and 4 papers in Immunology. Recurrent topics in Stephan Bart's work include Respiratory viral infections research (7 papers), Viral Infections and Outbreaks Research (6 papers) and Viral gastroenteritis research and epidemiology (5 papers). Stephan Bart is often cited by papers focused on Respiratory viral infections research (7 papers), Viral Infections and Outbreaks Research (6 papers) and Viral gastroenteritis research and epidemiology (5 papers). Stephan Bart collaborates with scholars based in United States, Netherlands and Belgium. Stephan Bart's co-authors include Giovanni Della Cioppa, Matthew Hohenboken, Vas Narasimhan, Philip R. Dormitzer, Niranjan Kanesa-thasan, Macaya Douoguih, Benoît Callendret, Christy Comeaux, Arangassery Rosemary Bastian and Els De Paepe and has published in prestigious journals such as New England Journal of Medicine, PLoS ONE and The Journal of Infectious Diseases.

In The Last Decade

Stephan Bart

19 papers receiving 423 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and Safety of an Ad26.RSV.preF–RSV preF Protein Vaccine in Older Adults

2023 90 citations Ann R. Falsey, Kristi L. Williams et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Stephan Bart United States	11	303	222	69	53	46	19	438
Monika Redlberger‐Fritz Austria	15	480 1.6×	245 1.1×	84 1.2×	59 1.1×	91 2.0×	44	655
Maria Pisareva Russia	12	447 1.5×	196 0.9×	46 0.7×	41 0.8×	48 1.0×	58	529
Alexander Doroshenko Canada	11	246 0.8×	181 0.8×	29 0.4×	45 0.8×	22 0.5×	27	394
Erin Sparrow Switzerland	13	327 1.1×	174 0.8×	63 0.9×	82 1.5×	48 1.0×	24	468
Amary Fall Senegal	13	300 1.0×	313 1.4×	21 0.3×	37 0.7×	64 1.4×	47	513
Tyler Bristol United States	9	597 2.0×	262 1.2×	169 2.4×	99 1.9×	51 1.1×	12	785
Neil Formica Australia	10	296 1.0×	181 0.8×	87 1.3×	50 0.9×	13 0.3×	11	457
Nungruthai Suntronwong Thailand	16	279 0.9×	448 2.0×	85 1.2×	137 2.6×	35 0.8×	52	686
Ariadna Rando‐Segura Spain	13	342 1.1×	215 1.0×	32 0.5×	52 1.0×	12 0.3×	75	605
Alla Heider Germany	10	378 1.2×	127 0.6×	60 0.9×	23 0.4×	16 0.3×	15	444

Countries citing papers authored by Stephan Bart

Since Specialization

Citations

This map shows the geographic impact of Stephan Bart's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephan Bart with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephan Bart more than expected).

Fields of papers citing papers by Stephan Bart

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stephan Bart. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephan Bart. The network helps show where Stephan Bart may publish in the future.

Co-authorship network of co-authors of Stephan Bart

This figure shows the co-authorship network connecting the top 25 collaborators of Stephan Bart. A scholar is included among the top collaborators of Stephan Bart based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stephan Bart. Stephan Bart is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Shaw, Christine A., Allison August, Stephan Bart, et al.. (2023). A phase 1, randomized, placebo-controlled, dose-ranging study to evaluate the safety and immunogenicity of an mRNA-based chikungunya virus vaccine in healthy adults. Vaccine. 41(26). 3898–3906. 23 indexed citations

Comeaux, Christy, Stephan Bart, Arangassery Rosemary Bastian, et al.. (2023). Safety, Immunogenicity, and Regimen Selection of Ad26.RSV.preF–Based Vaccine Combinations: A Randomized, Double-blind, Placebo-Controlled, Phase 1/2a Study. The Journal of Infectious Diseases. 229(1). 19–29. 15 indexed citations

Falsey, Ann R., Kristi L. Williams, Stephan Bart, et al.. (2023). Efficacy and Safety of an Ad26.RSV.preF–RSV preF Protein Vaccine in Older Adults. New England Journal of Medicine. 388(7). 609–620. 90 indexed citations breakdown →

Bockstal, Viki, Georgi Shukarev, Chelsea McLean, et al.. (2022). First-in-human study to evaluate safety, tolerability, and immunogenicity of heterologous regimens using the multivalent filovirus vaccines Ad26.Filo and MVA-BN-Filo administered in different sequences and schedules: A randomized, controlled study. PLoS ONE. 17(10). e0274906–e0274906. 19 indexed citations

Comeaux, Christy, Ann R. Falsey, Kristi Williams, et al.. (2022). 2321. Long-term immunogenicity of Ad26.RSV.preF/RSV preF protein vaccine against RSV in a phase 2b study by age and risk level. Open Forum Infectious Diseases. 9(Supplement_2). 2 indexed citations

Bockstal, Viki, Auguste Gaddah, Neil Goldstein, et al.. (2021). Assessments of different batches and dose levels of a two-dose Ad26.ZEBOV and MVA-BN-Filo vaccine regimen. npj Vaccines. 6(1). 157–157. 8 indexed citations

Falsey, Ann R., Kristi L. Williams, Stephan Bart, et al.. (2021). LB14. Efficacy and Immunogenicity of an Ad26.RSV.preF-based Vaccine in the Prevention of RT-PCR-confirmed RSV-mediated Lower Respiratory Tract Disease in Adults Aged ≥65 Years: A Randomized, Placebo-controlled, Phase 2b Study. Open Forum Infectious Diseases. 8(Supplement_1). S812–S812. 10 indexed citations

Tasker, Sybil, Stephan Bart, Vyjayanthi Krishnan, et al.. (2021). Safety and Immunogenicity of a Novel Intranasal Influenza Vaccine (NasoVAX): A Phase 2 Randomized, Controlled Trial. Vaccines. 9(3). 224–224. 15 indexed citations

Cartee, Robert T., et al.. (2020). A phase 1 randomized safety, reactogenicity, and immunogenicity study of Typhax: A novel protein capsular matrix vaccine candidate for the prevention of typhoid fever. PLoS neglected tropical diseases. 14(1). e0007912–e0007912. 5 indexed citations

10.

Peters, Erica N., Evan S. Herrmann, Jess Wilhelm, et al.. (2020). Impact of smoked cannabis on tobacco cigarette smoking intensity and subjective effects: A placebo-controlled, double-blind, within-subjects human laboratory study.. Experimental and Clinical Psychopharmacology. 29(4). 345–354. 4 indexed citations

11.

Goldstein, Neil, Viki Bockstal, Stephan Bart, et al.. (2020). Safety and Immunogenicity of Heterologous and Homologous 2-Dose Regimens of Adenovirus Serotype 26– and Modified Vaccinia Ankara–Vectored Ebola Vaccines: A Randomized, Controlled Phase 1 Study. The Journal of Infectious Diseases. 226(4). 595–607. 24 indexed citations

12.

Standaert, Baudouin, Stephan Bart, Laurence Chu, et al.. (2019). Usability of daily SF36 questionnaires to capture the QALD variation experienced after vaccination with AS03A-adjuvanted monovalent influenza A (H5N1) vaccine in a safety and tolerability study. Health and Quality of Life Outcomes. 17(1). 80–80. 8 indexed citations

13.

Shaw, Christine A., Lori Panther, Allison August, et al.. (2019). Safety and immunogenicity of a mRNA-based chikungunya vaccine in a phase 1 dose-ranging trial. International Journal of Infectious Diseases. 79. 17–17. 26 indexed citations

14.

Tasker, Sybil, et al.. (2018). 2554. Safety and Immunogenicity of NasoVAX, a Novel Intranasal Influenza Vaccine. Open Forum Infectious Diseases. 5(suppl_1). S68–S68. 4 indexed citations

15.

Falloon, Judith, Fei Ji, Craig Curtis, et al.. (2016). A phase 1a, first-in-human, randomized study of a respiratory syncytial virus F protein vaccine with and without a toll-like receptor-4 agonist and stable emulsion adjuvant. Vaccine. 34(25). 2847–2854. 50 indexed citations

16.

Douoguih, Macaya, Neil Goldstein, Stephan Bart, et al.. (2016). Safety and immunogenicity of heterologous Ad26.ZEBOV and MVA-BN®-Filo prime-boost Ebola vaccines: 6-month follow-up of a Phase I randomized trial in healthy adults. Journal of Virus Eradication. 2. 10–11. 1 indexed citations

17.

Bart, Stephan, et al.. (2016). Immunogenicity and safety of a cell culture-based quadrivalent influenza vaccine in adults: A Phase III, double-blind, multicenter, randomized, non-inferiority study. Human Vaccines & Immunotherapeutics. 12(9). 2278–2288. 39 indexed citations

18.

Bart, Stephan, Matthew Hohenboken, Giovanni Della Cioppa, et al.. (2014). A Cell Culture–Derived MF59-Adjuvanted Pandemic A/H7N9 Vaccine Is Immunogenic in Adults. Science Translational Medicine. 6(234). 234ra55–234ra55. 78 indexed citations

19.

Bart, Stephan, Joachim Marr, Konstanze Diefenbach, Dietmar Trummer, & Carole Sampson-Landers. (2011). Folate status and homocysteine levels during a 24-week oral administration of a folate-containing oral contraceptive: a randomized, double-blind, active-controlled, parallel-group, US-based multicenter study. Contraception. 85(1). 42–50. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact